Analytical issues on prostate-specific antigen in relation to prostate cancer screening

Clinical Biochemistry

Volumn 31, Issue 8, 1998, Pages 633-639

  Blijenberg, Bert G ^a   Roobol, Monique ^a   Schröder, Fritz H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Evaluation; Prostate cancer screening; Prostate specific antigen; Standardization

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; REAGENT;

ACCURACY; ARTICLE; CALIBRATION; CANCER SCREENING; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; NETHERLANDS; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY CONTROL; RELIABILITY; STORAGE;

HUMANS; IMMUNOASSAY; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 0032421359     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9120(98)00072-1     Document Type: Article

References (22)

1. Boyle P., Maisonneuve P., Napalkov P. Geographical and temporal patterns of incidence and mortality from prostate cancer. Urology. 46:(Suppl 3A):1995;47-55.
2. Bentvelsen F.M., Schröder F.H. Modalities available for screening for prostate cancer. Eur J Cancer. 29A:1993;804-811.
3. Denis L.J. Prostate cancer screening and prevention "realities and hope" Urology. 46:(Suppl 3A):1995;56-61.
4. Alexander FE. Rationale for trials of screening for prostate cancer. In: Recent advantages in prostate cancer and BPH. Proceedings of the Fourth Congress on Progress and Controversies in Oncological Urology, Rotterdam, The Netherlands, April 1996. (Ed. Schröder FH), Pp. 159-66, New York: Parthenon Publishing Group, 1997.
5. Parkes C.A. An epidemiologist's viewpoint on screening. Cancer Surveys. 23:1995;127-139.
6. Schröder F.H., Damhuis R.A.M., Kirkels W.J., De Koning H.J., Kranse R., Nijs H.G.T., Blijenberg B.G. European randomized study of screening for prostate cancer - the Rotterdam Pilot Studies. Int J Cancer. 65:1996;145-151.
7. Auvinen A, Calais da Silva F, Denis LJ, Hugosson J, Schröder FH. The European Randomized Study of Screening for Prostate Cancer (ERSPC): International cooperation and preliminary data. In: Recent advantages in prostate cancer and BPH. Proceedings of the Fourth Congress on Progress and Controversies in Oncological Urology, Rotterdam, The Netherlands, April 1996.(Ed. Schröder FH), Pp. 167-73, New York: Parthenon Publishing Group, 1997.
8. Schröder F.H., Damhuis R.A.M., Kirkels W.J., et al. European randomized study of screening for prostate cancer - the Rotterdam pilot studies. Int J Cancer. 65:1996;145-151.
9. Passing H., Bablok W. A new biomedical procedure for testing the equality of measurements from two different analytical methods. J Clin Chem Clin Biochem. 21:1983;709-720.
10. Bland J.M., Altman D.G. Statistical methods for agreement between two methods of clinical measurement. Lancet. i:1986;307-310.
11. Hollis S. Analysis of method comparison studies. Ann Clin Biochem. 33:1996;1-4.
12. Simm B., Gleeson M. Storage conditions for estimating prostate-specific antigen. Clin Chem. 37:1991;113-114.
13. Piironen T., Pettersson K., Suonpää M., Stenman U.-H., Oesterling J.E., Lövgren T., Lilja H. In vitro stability of free prostate-specific antigen (PSA) and prostate-specific antigen (PSA) complexed to α 1-chymotrypsin in blood samples. Urology. 48:1996;81-87.
14. Blijenberg B.G., Kranse R., Eman I., Schröder F.H. Some analytical considerations on the measurement of prostate-specific antigen. Eur J Clin Chem Clin Biochem. 34:1996;817-821.
15. Stamey T.A. Second Stanford conference on international standardization of prostate-specific antigen immunoassays September 1 and 2, 1994 . Urology. 45:1995;173-184.
16. NCCLS Document I/LA 19-A. Primary reference preparations for standardization and calibration of immunochemical assays for serum prostate-specific antigen (PSA); Approved guideline; Wayne, Pennsylvania, 1996.
17. Bangma C.H., Kranse R., Blijenberg B.G., Schröder F.H. The value of screening tests in the detection of prostate cancer. Part 2: retrospective analysis of free/total prostate-specific antigen ratio, age-specific reference ranges and PSA density . Urology. 46:1995;779-784.
18. Rietbergen J.B.W., Kranse R., Kirkels W.J., De Koning H.J., Schröder F.H. Evaluation of prostate-specific antigen, digital rectal examination and transrectal ultrasonography in population-based screening for prostate cancer; improving the efficiency of early detection. Br J Urol. 79:(Suppl 2):1997;57-63.
19. Van Dalen A. Quality control and standardization of tumour marker tests. Tumor Biol. 14:1993;131-135.
20. Komatsu K., Wehner N., Prestigiacomo A.F., Chen Z., Stamey T.A. Physiologic (intraindividual) variation of serum prostate-specific antigen in 814 men from a screening population. Urology. 47:1996;343-346.
21. Nixon R.G., Wener M.H., Smith K.M., Parson R.E., Strobel S.E., Brawer M.K. Biological variation of prostate-specific antigen levels in serum an evaluation of day-to-day physiological fluctuations in a well-defined cohort of 24 patients . J Urol. 157:1997;2183-2190.
22. Büttner J. Reference materials and reference methods in laboratory medicine a challenge to international cooperation . Eur J Clin Chem Clin Biochem. 32:1994;571-577.